Longboard Pharmaceuticals (NASDAQ:LBPH – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a research note issued on Friday, Benzinga reports. They currently have a $60.00 target price on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 178.68% from the company’s current price. Other […]
HC Wainwright reaffirmed their buy rating on shares of Longboard Pharmaceuticals (NASDAQ:LBPH – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $60.00 price objective on the stock. LBPH has been the topic of a number of other reports. Guggenheim increased their price objective on […]
Citigroup began coverage on shares of Longboard Pharmaceuticals (NASDAQ:LBPH – Free Report) in a research report sent to investors on Friday, Marketbeat reports. The firm issued a buy rating and a $40.00 price target on the stock. Several other equities analysts have also recently weighed in on the company. Cantor Fitzgerald raised their price objective […]
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 2,440,000 shares, a growth of 43.5% from the January 15th total of 1,700,000 shares. Based on an average daily volume of 1,200,000 shares, […]
Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $23.15, but opened at $23.87. Longboard Pharmaceuticals shares last traded at $22.52, with a volume of 40,554 shares trading hands. Analyst Ratings Changes LBPH has been the subject of a number […]